Compare RVL Pharmaceuticals Plc with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%
RVL Pharmaceuticals Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-37.80%
EBIT Growth (5y)
-195.74%
EBIT to Interest (avg)
-11.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
2.38
Sales to Capital Employed (avg)
0.45
Tax Ratio
0.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
23.91%
ROCE (avg)
0.69%
ROE (avg)
0.94%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.89
EV to EBITDA
-0.90
EV to Capital Employed
0.70
EV to Sales
1.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-79.05%
ROE (Latest)
-229.87%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2023
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 8 Schemes (1.97%)
Foreign Institutions
Held by 8 Foreign Institutions (0.26%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'23 - YoY
Jun'23
Jun'22
Change(%)
Net Sales
8.30
8.40
-1.19%
Operating Profit (PBDIT) excl Other Income
-8.00
-15.00
46.67%
Interest
0.00
1.00
-100.00%
Exceptional Items
-16.20
4.20
-485.71%
Consolidate Net Profit
-23.90
-12.10
-97.52%
Operating Profit Margin (Excl OI)
-983.40%
-1,790.20%
80.68%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2023 is -1.19% vs -26.96% in Jun 2022
Consolidated Net Profit
YoY Growth in quarter ended Jun 2023 is -97.52% vs 45.00% in Jun 2022
Annual Results Snapshot (Consolidated) - Dec'22
Dec'22
Dec'21
Change(%)
Net Sales
49.70
17.50
184.00%
Operating Profit (PBDIT) excl Other Income
-45.40
-70.50
35.60%
Interest
3.10
3.00
3.33%
Exceptional Items
-9.20
-7.80
-17.95%
Consolidate Net Profit
-51.70
-82.80
37.56%
Operating Profit Margin (Excl OI)
-920.70%
-4,497.50%
357.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2022 is 184.00% vs -37.05% in Dec 2021
Consolidated Net Profit
YoY Growth in year ended Dec 2022 is 37.56% vs 6.97% in Dec 2021
About RVL Pharmaceuticals Plc 
RVL Pharmaceuticals Plc
Pharmaceuticals & Biotechnology
Osmotica Pharmaceuticals plc is an integrated biopharmaceutical company. The Company is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The Company sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).
Company Coordinates 
Company Details
400 Crossing Blvd , BRIDGEWATER NJ : 08807-2863
Registrar Details






